Effect of deglutition aids on the inhibitory effect of orally disintegrating tablets of voglibose on the postprandial elevation of blood glucose levels: a case investigating the interaction between xanthan gum and voglibose.

Blood glucose elevation Jelly-wafer Orally disintegrating tablet Voglibose Xanthan gum

Journal

Diabetology international
ISSN: 2190-1678
Titre abrégé: Diabetol Int
Pays: Japan
ID NLM: 101553224

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 11 12 2017
accepted: 27 08 2018
entrez: 26 2 2019
pubmed: 26 2 2019
medline: 26 2 2019
Statut: epublish

Résumé

In this study, we first performed a disintegration test of the voglibose orally disintegrating (V-OD) tablet immersed in jelly-wafer (JW, V-ODims/jw) for 10 min and compared it with the disintegration time of V-OD that was not immersed in JW. We then orally administered the V-ODims/jw tablet to 7 healthy adults and compared the shift in blood glucose levels (BGLs), after loading with a sucrose solution (Suc-sol, 100 g/150 mL), with that after administration of the non-immersed V-OD tablet. The disintegration time of V-ODims/jw tablet was shorter than that of V-OD. When administered to healthy adults, the BGL after loading with Suc-sol was higher with V-ODims/jw tablet administration than with V-OD tablet. We predict that the expression of the efficacy of voglibose is reduced as a result of the interaction between voglibose and the polysaccharide, xanthan gum (XG), since it is a common additive in JW. This study shows that deglutition aids with additives that do not affect pharmacokinetics must be carefully selected for administering along with pharmaceuticals, because of a suggested possibility that the interaction between these pharmaceuticals and the additives in the deglutition aids weaken the drug efficacy. A more careful selection of deglutition aids from the wide selection of medication is especially important when administered to patients who use these deglutition aids often, such as elderly individuals or individuals with a deglutition disorder.

Identifiants

pubmed: 30800566
doi: 10.1007/s13340-018-0372-0
pii: 372
pmc: PMC6357238
doi:

Types de publication

Journal Article

Langues

eng

Pagination

77-82

Déclaration de conflit d'intérêts

None of the authors have any conflicts of interest associated with this study.This study was carried out in accordance with the Declaration of Helsinki of 1964 and later versions and approved by the ethics committee of Hospital BANDO (approval number: not applicable, approval date: 8 March 2017).The healthy Japanese adult males gave their written informed consent to participate in this study and its results to be published.

Références

Diabetes Care. 2002 Jun;25(6):956-60
pubmed: 12032098
Ann Intern Med. 1991 Jun 15;114(12):1020-4
pubmed: 2029097
Diabetes Care. 2011 Mar;34(3):596-7
pubmed: 21282342
Yakugaku Zasshi. 2015;135(6):835-40
pubmed: 26028419
Yakugaku Zasshi. 2016;136(8):1171-6
pubmed: 27477734

Auteurs

Takashi Tomita (T)

1Department of Clinical Pharmaceutics and Pharmacy Practice, School of Pharmacy, Iwate Medical University, 2-1-1, Nishitokuta, Yahabacho, Shiwagun, Iwate 028-3694 Japan.
Department of Pharmacy, Hospital Bando, 411 Kutsukake, Bando, Ibaraki 306-0515 Japan.

Hidekazu Goto (H)

Department of Pharmacy, Hospital Bando, 411 Kutsukake, Bando, Ibaraki 306-0515 Japan.

Kenji Sumiya (K)

3Faculty of Pharmacy, Iwaki Meisei University, 5-5-1 Chuodai Iino, Iwaki, Fukushima 970-8551 Japan.

Tadashi Yoshida (T)

Department of Internal Medicine, Hospital Bando, 411 Kutsukake, Bando, Ibaraki 306-0515 Japan.

Kenzo Kudo (K)

1Department of Clinical Pharmaceutics and Pharmacy Practice, School of Pharmacy, Iwate Medical University, 2-1-1, Nishitokuta, Yahabacho, Shiwagun, Iwate 028-3694 Japan.

Yukinao Kohda (Y)

Department of Pharmacy, Hospital Bando, 411 Kutsukake, Bando, Ibaraki 306-0515 Japan.
5Faculty of Health Sciences, Tsukuba International University, 6-20-1 Manabe, Tsuchiura, Ibaraki 300-0051 Japan.

Classifications MeSH